Requires prescription benefit managers to approve a specific medication prescribed by a doctor when supported by a notarized medical necessity letter and requires that any denial be reviewed and documented by a licensed medical expert.
Impact
The legislation is designed to directly impact the interactions between healthcare providers, patients, and PBMs, fostering greater transparency and accountability in medication management. By requiring that any denial of coverage for a prescribed medication undergo a review by a licensed healthcare professional, this bill aims to protect patients from arbitrary decisions made by PBMs that may not be rooted in medical expertise. Its introduction reflects a growing recognition of the challenges patients face in accessing necessary medications.
Summary
House Bill H7814, known as the Prescription Benefit Manager Accountability Act, seeks to enhance accountability for prescription benefit managers (PBMs) in Rhode Island. The bill mandates that PBMs must approve specific medications prescribed by healthcare practitioners if supported by a notarized letter that outlines the medical necessity of the prescription. This initiative aims to streamline the process for patients needing specific medications, aiming to eliminate unnecessary denial or substitution of prescribed drugs.
Contention
Despite its positive intentions, the bill may face opposition from some industry stakeholders who could argue that it imposes excessive regulations on PBMs, potentially leading to increased costs for healthcare providers and insurers. Critics might express concerns over how these requirements could affect the efficiency of medication approval processes. As debates unfold, the balance between ensuring patient access to medically necessary prescriptions and maintaining operational efficiency in healthcare administration will be a critical point of contention.
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Requires the department of elementary and secondary education and DOH to adopt policies, rules and regulations for the administration of seizure rescue medications for children who have been medically identified as having epilepsy/seizure disorder.
Establishes the process to provide a legal mechanism whereby a terminally ill patient may choose to end their life using medications prescribed by a physician.
Establishes the process to provide a legal mechanism whereby a terminally ill patient may choose to end their life using medications prescribed by a physician.